Biodistribution and plasma protein binding of zoledronic acid

Drug Metabolism and Disposition

Volumn 36, Issue 10, 2008, Pages 2043-2049

  Weiss, H Markus ^a   Pfaar, Ulrike ^a   Schweitzer, Alain ^a   Wiegand, Hansjörg ^a   Skerjanec, Andrej ^a   Schran, Horst ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; CANCELLOUS BONE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ANIMALS; AREA UNDER CURVE; AUTORADIOGRAPHY; BLOOD PROTEINS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOGS; FECES; IMIDAZOLES; MALE; PROTEIN BINDING; RATS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

CANIS FAMILIARIS; RATTUS;

EID: 52949134055     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.021071     Document Type: Article

References (35)

1. Barrett J, Worth E, Bauss F, and Epstein S (2004) Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 44:951-965.
2. Bauss F and Russell RG (2004) Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 15:423-433.
3. Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, and Seaman JJ (1997) Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 37:285-290.
4. Bergner R, Henrich DM, Hoffmann M, Honecker A, Mikus G, Nauth B, Nagel D, and Uppenkamp M (2007) Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol 47:942-950.
5. Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J, Cosman F, Lakatos P, Leung P, Man Z, et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New Eng J Med 356:1809-1822.
6. Body JJ, Pfister T, and Bauss F (2005) Preclinical perspectives on bisphosphonate renal safety. Oncologist 10(Suppl 1):3-7.
7. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino F, Colombel M, Delmas P, Delaisse J, and Clezardin P (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949-2954.
8. Botta L, Gerber HU, and Schmid K (1985) Measurement of radioactivity in biological experiments, in Drug Fate and Metabolism, Methods and Techniques (Garrett ER and Hirtz JL eds) vol 5, pp 99-134, Dekker, New York.
9. Bounameaux HM, Schifferli J, Montani JP, Jung A, and Chatelanat F (1983) Renal failure associated with intravenous diphosphonates. Lancet 1:471.
10. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, et al. (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:1228-1236.
11. Cremers SC, Pillai G, and Papapoulos SE (2005) Pharmacokinetics/ pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharma-cokinet 44:551-570.
12. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
13. Dooley M and Balfour J (1999) Ibandronate. Drugs 57:101-108.
14. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, and Porras AG (1993) Clinical pharmacology of alendronate sodium. Osteoporosis Int 3(Suppl 3): S13-S16.
15. Green JR, Müller K, and Jaeggi KA (1994) Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751.
16. Johnston RF, Pickett SC, and Barker DL (1990) Autoradiography using storage phosphor technology. Electrophoresis 11:355-360.
17. Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, and Russell RG (1983) Effects of intravenous diphosphonates on renal function. Lancet 1:1328.
18. Kasting GB and Francis MD (1992) Retention of etidronate in human, dog and rat. J Bone Miner Res 7:513-522.
19. Kino I, Kato Y, Lin JH, and Sugiyama Y (1999) Renal handling of bisphosphonate alendronate in rats. Biopharm Drug Dispos 20:193-198.
20. Lewiecki EM and Miller PD (2007) Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf 6:663-672.
21. Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75-85.
22. Lin JH, Chen IW, and deLuna FA (1994) Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake. Drug Metab Dispos 22:400-405.
23. Lin JH, Chen IW, deLuna FA, and Hichens M (1993) Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats. J Pharmacol Exp Ther 267:670-675.
24. Lin JH, Duggan DE, Chen IW, and Ellsworth RL (1991) Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 19:926-932.
25. Lin JH, Russell G, and Gertz B (1999) Pharmacokinetics of alendronate: an overview. Int J Clin Pract Suppl 101:18-26.
26. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, and Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589.
27. Martin-Jimenez T, de Lorimier LP, Fan TM, and Freise KJ (2007) Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs. J Vet Pharmacol Ther 30:492-495.
28. Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ, and Body JJ (1996) Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 11:587-593.
29. Pongchaidecha M and Daley-Yates PT (1993) Clearance and tissue uptake following 4-hour and 24-hour infusions of pamidronate in rats. Drug Metab Dispos 21:100-104.
30. Rosen L, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, et al. (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21:3150-3157.
31. Saha H, Castren-Kortekangas P, Ojanen S, Juhakoski A, Tuominen J, Tokola O, and Pasternack A (1994) Pharmacokinetics of clodronate in renal failure. J Bone Miner Res 9:1953-1958.
32. 14C-whole-body autoradiograms. Int J Rad Appl Instrum [A] 38:329-333.
33. Singer FR and Minoofar PN (1995) Bisphosphonates in the treatment of disorders of mineral metabolism. Adv Endocrinol Metab 6:259-288.
34. Skerjanec A, Berenson J, Hsu C, Major P, Miller WH, Jr., Ravera C, Schran H, Seaman J, and Waldmeier F (2003) The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 43:154-162.
35. Ullberg S (1977) The technique of whole-body autoradiography: cryosectioning of large specimens, in Science Tools (Alvfeldt O, ed) LKB-Producter AB, Sweden.